8-K: Akero Therapeutics Announces Positive Q2 Results and Advances Efruxifermin Clinical Program

Akero Therapeutics reported its second quarter 2024 financial results, highlighted by the initiation of a Phase 3 trial for Efruxifermin (EFX) and expansion of its leadership team.

Summary

• Akero Therapeutics announced its financial results for the second quarter of 2024, ending June 30, 2024.
• The company initiated the Phase 3 SYNCHRONY Outcomes trial for Efruxifermin (EFX) in patients with compensated cirrhosis due to MASH.
• Akero presented positive data from the Phase 2b HARMONY study at the EASL Congress 2024, showing significant fibrosis improvement with EFX.
• Scott Gangloff was appointed as Chief Technical Officer to support manufacturing and supply chain.
• The company's cash, cash equivalents, and marketable securities totaled $848.3 million as of June 30, 2024.
• Akero believes its current funds will support operations into the second half of 2027.
• Research and development expenses for the quarter were $55.3 million, up from $28.0 million in the same period last year.
• Total operating expenses for the quarter were $65.7 million, compared to $35.6 million in the same period last year.
• The net loss for the quarter was $55.987 million, compared to a net loss of $31.083 million for the same period last year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results, a solid cash position, and the initiation of a Phase 3 trial. The increase in expenses and net loss are expected for a company in this stage of development, but the overall tone is optimistic.

Positives

• The initiation of the Phase 3 SYNCHRONY Outcomes trial is a significant step forward for EFX.
• The Phase 2b HARMONY study results demonstrate strong efficacy of EFX in improving fibrosis.
• The appointment of a Chief Technical Officer strengthens the company's manufacturing capabilities.
• The company has a strong cash position of $848.3 million.
• The company has sufficient funding to support operations into the second half of 2027.
• EFX was generally well tolerated in clinical trials with no drug-induced liver injury or deaths.

Negatives

• Research and development expenses increased significantly to $55.3 million for the quarter.
• Total operating expenses increased to $65.7 million for the quarter.
• The net loss for the quarter was $55.987 million, an increase from the $31.083 million loss in the same period last year.

Risks

• The success of clinical trials is not guaranteed, and positive results from earlier studies may not predict future outcomes.
• Regulatory approvals are subject to uncertainty and may be delayed or denied.
• The company's ability to fund operations depends on its cash reserves and potential future financing.
• The company faces competition from other companies developing treatments for MASH.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Akero expects its current cash reserves to fund operations into the second half of 2027, including the Phase 3 SYNCHRONY Histology and Real-World studies through their primary endpoint readouts. The company anticipates reporting week 96 results from the Phase 2b SYMMETRY study in the first quarter of 2025.

Management Comments

• The second quarter of 2024 brought important progress for EFX with the initiation of the Phase 3 SYNCHRONY Outcomes trial and appointment of a chief technical officer, said Andrew Cheng, president and CEO.
• Initiation of the final planned trial in the Phase 3 SYNCHRONY program and expansion of our leadership team strengthen Akeros position to advance our EFX program, bringing us closer to providing this potentially transformative therapy to patients in need.

Industry Context

This announcement is significant in the context of the growing need for effective treatments for MASH, a serious liver disease. Akero's progress with EFX positions them as a key player in this space, competing with other companies developing therapies for similar conditions. The positive data from the HARMONY study and the initiation of the Phase 3 trial are important milestones in the development of EFX.

Comparison to Industry Standards

• The 75% response rate for 1-stage fibrosis improvement with 50mg EFX in the HARMONY study is highly competitive compared to other MASH treatments in development.
• The 36% of patients achieving a 2-stage improvement in fibrosis is also a strong result, exceeding the performance of many other experimental therapies.
• The safety profile of EFX, with no drug-induced liver injury or deaths, is also a positive differentiator.
• Companies such as Madrigal Pharmaceuticals and Intercept Pharmaceuticals are also developing treatments for MASH, and Akero's results will be closely compared to their clinical trial data.

Management Changes

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results and strong cash position favorably.
• Employees may be encouraged by the company's progress and growth.
• Patients with MASH may benefit from the development of EFX as a potential treatment option.
• Suppliers and partners may see increased business opportunities with Akero.

Next Steps

• Continue enrollment in the Phase 3 SYNCHRONY clinical trials.
• Report week 96 results from the Phase 2b SYMMETRY study in the first quarter of 2025.
• Advance the development of EFX towards potential regulatory approval.
• Continue to build out manufacturing capabilities for EFX.

Key Dates

Keywords

Efruxifermin, MASH, NASH, Fibrosis, Clinical Trial, Phase 3, Liver Disease, Metabolic Disease, Akero Therapeutics, Biotechnology